Evidence map›Paper›PMID 40316009›Full record

ReviewJournal of molecular biology2025

Hepatitis B Virus Nucleocapsid Assembly.

Xupeng Hong, William M Schneider, Charles M Rice

Abstract readReview
In one paragraph

Review in Journal of molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. New Advances in Small Molecules Targeted at Viral Capsid-Genome Binding.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xupeng HongLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA. Electronic address: xhong@rockefeller.edu.
William M SchneiderLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.
Charles M RiceLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.

Funding

Launching HBV with RNA to assess antiviral resistance and explore fundamental aspects of virus-host biologyR01AI150275 · NIAID · ROCKEFELLER UNIVERSITY · PI Charles M Rice · 2020 to 2026
$4.4M
In search of an HBV cure: novel model systems and targetsR01AI143295 · NIAID · ROCKEFELLER UNIVERSITY · PI RICE, CHARLES M · 2019 to 2023
$3.0M
Breaching the species barrier: Towards an immunocompetent HBV-susceptible mouse modelR01AI183884 · NIAID · ROCKEFELLER UNIVERSITY · PI Charles M Rice · 2024 to 2026
$2.4M
NIAID NIH HHS R01 AI143295NIAID NIH HHS R01 AI150275NIAID NIH HHS R01 AI183884
6 · The paper itself

Abstract

Hepatitis B virus (HBV), the prototypical member of the Hepadnaviridae family, is a DNA virus that replicates its genome through reverse transcription of a pregenomic RNA (pgRNA) precursor. The selective packaging of pgRNA and viral polymerase (Pol) into assembling capsids formed by the viral core protein-a process known as nucleocapsid assembly-is an essential step in the HBV lifecycle. Advances in cellular and cell-free systems have provided significant insights into the mechanisms underlying capsid assembly, Pol binding to pgRNA, Pol-pgRNA packaging, and initiation of genome replication. However, the absence of a cell-free system capable of reconstituting selective HBV Pol-pgRNA packaging into fully assembled capsids leaves fundamental questions about nucleocapsid assembly unanswered. This review summarizes the current knowledge of HBV nucleocapsid assembly, focusing on the interplay between Pol-pgRNA interactions, capsid formation, and regulation by host factors. It also highlights the contribution of cellular and cell-free systems to these discoveries and underscores the need for new approaches that reconstitute the complete HBV nucleocapsid assembly process. With the growing interest in developing nucleocapsid assembly inhibitors, some of which are currently in clinical trials, targeting Pol-pgRNA interactions and nucleocapsid assembly represents a promising therapeutic strategy for curing chronic hepatitis B.

Indexed as

Hepatitis B virusNucleocapsidVirus AssemblyCapsidHumansRNARNA, ViralVirus ReplicationpgRNARNARNA, Viralgenome packaginghepatitis B virushost factornucleocapsid assemblyviral polymerase

Identifiers

PMID40316009
PMCPMC12353522

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.